Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Lucid Diagnostics to related businesses based on the strength of its risk, institutional ownership, profitability, analyst recommendations, dividends, earnings and valuation.
Profitability
This table compares Lucid Diagnostics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -959.76% | N/A | -119.57% |
| Lucid Diagnostics Competitors | -9,046.59% | -199.78% | -30.61% |
Risk & Volatility
Lucid Diagnostics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Lucid Diagnostics’ peers have a beta of 1.16, indicating that their average stock price is 16% more volatile than the S&P 500.
Earnings & Valuation
This table compares Lucid Diagnostics and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | -$58.01 million | -0.85 |
| Lucid Diagnostics Competitors | $691.14 million | $10.43 million | -15.00 |
Lucid Diagnostics’ peers have higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings for Lucid Diagnostics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Lucid Diagnostics Competitors | 9828 | 15118 | 45430 | 1585 | 2.54 |
Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 952.14%. As a group, “Biotechnology” companies have a potential upside of 102.50%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Lucid Diagnostics is more favorable than its peers.
Summary
Lucid Diagnostics beats its peers on 8 of the 13 factors compared.
Lucid Diagnostics Company Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
